Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations

References

• Wasley A, Miller, JT, Finelli L, Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis – United States, 2005. MMWR Surveill. Summ.56(3), 1–24 (2007).
   PubMedGoogle Scholar
• Poynard T, Leroy V Cohard M et al. for the Consensus Interferon Study Group. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology24, 778–789 (1996).
   PubMed Web of Science ®Google Scholar
• Wills RJ. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet.19, 390–399 (1990).
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon-α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet352(9138), 1426–1432 (1998).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med.339(21), 1485–1492 (1998).
   PubMed Web of Science ®Google Scholar
• Lindsay K, Trepo C, Heintges T; for the Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology34(2), 395–403 (2001).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med.347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• PEG -Intron™, package insert. Schering, Kenilworth, NJ, USA (2001).
   Google Scholar
• Pawlotsky JM, McHutchison JG. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, USA February 27–March 1, 2003. Hepatology39(2), 554–567 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobson, IM, Gonzalez SA, Ahmed F et al. A randomized trial of pegylated interferon α-2b plus ribavirin in the retreatment of chronic hepatitis C. Am. J. Gastroenterol.100(11), 2453–2462 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin. Infect. Dis.42, 1674–1678 (2006).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin. Liver Dis.9(4), 601–616 (2005).
   PubMedGoogle Scholar
• Reddy KR, Shiffman ML, Morgan TR et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon α-2a/ribavirin treatment. Clin. Gastroenterol. Hepatol.5(1), 124–129 (2007).
   PubMed Web of Science ®Google Scholar
• Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon α and ribavirin. J. Clin. Gastroenterol.39(1 Suppl.), S9–S13 (2005).
   Web of Science ®Google Scholar
• Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin α. Hepatology46(2), 371–379 (2007).
   PubMed Web of Science ®Google Scholar
• Lindsay KL, TC, Heintges T, Introduction to therapy of hepatitis C. Hepatology36, S114–S120 (2002).
   Google Scholar
• Denis F, Adjide CC, Rogez S, Delpeyroux C, Rogez JP, Weinbreck P. Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus. Pathol. Biol.45, 701–708 (1997).
   PubMed Web of Science ®Google Scholar
• Roca B, Suarez I, Gonzalez J et al. Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J. Infect.47, 117–124 (2003).
   Google Scholar
• Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin. Infect. Dis.34, 831–837 (2002).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann. Intern. Med.138, 197–201 (2003).
   PubMed Web of Science ®Google Scholar
• Pol S, Vallet-Pichard A, Fontaine H. Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy. J. Viral Hepat.9(1), 1–8 (2002).
   Google Scholar
• Lewden C, May T, Rosenthal E et al.; ANRS EN19 Mortalité Study Group and Mortavic1. Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J. Acquir. Immune Defic. Syndr.48(5), 590–598 (2008).
   PubMed Web of Science ®Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol.26(1), 1–5 (1997).
   PubMed Web of Science ®Google Scholar
• Mohsen AH, Easterbrook PJ, Taylor C et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut52(7), 1035–1040 (2003).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, DiMartino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology30(4), 1054–1058 (1999).
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis.33(4), 562–569 (2001).
   PubMed Web of Science ®Google Scholar
• Puoti M, Prestini K, Biasi L et al. Natural History of cirrhosis in HIV-HCV coinfected patients. Presented at: 2nd International Workshop on HIV and Hepatitis Coinfection. Amsterdam, The Netherlands, 12–14 January (2006) (Abstract 51).
   Google Scholar
• Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment, Clin. Infect. Dis.36, 97–100 (2003).
   PubMed Web of Science ®Google Scholar
• Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin. Infect. Dis.40, S349–S356 (2005).
   PubMed Web of Science ®Google Scholar
• Soriano V, Miro JM, Garcia-Samaniego J et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J. Viral Hepat.11(1), 2–17 (2004).
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med.351(5), 438–450 (2004).
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon α-2b vs standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA292(23), 2839–2848 (2004).
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco JL et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS18(13), F27–F36 (2004).
   Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med.343(23), 1673–1680 (2000).
   PubMed Web of Science ®Google Scholar
• Sherman M, Cohen L, Cooper MA et al. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can. J. Gastroenterol.20(7), 479–485 (2006).
   Google Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med.341, 556–562 (1999).
   PubMed Web of Science ®Google Scholar
• Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African–Americans: summary of a workshop. Gastroenterology119(5), 1385–1396 (2000).
   PubMedGoogle Scholar
• Jeffers LJ, Cassidy W, Howell CD et al. Peginterferon α-2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology39(6), 1702–1708 (2004).
   PubMed Web of Science ®Google Scholar
• Muir AJ, Bornstein JD, Killenberg PG. Peginterferon α-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med.350(22), 2265–2271 (2004).
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African–American and Caucasian–American patients with hepatitis C genotype 1. Gastroenterology131(2), 470–477 (2006).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Poynard T, Pianko S et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. the International Hepatitis Interventional Therapy Group. Gastroenterology119, 1317–1323 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobson I, Brown RJ; the the WIN-R Study Group. Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African–Americans (AA) compared to flat dose ribavirin with peginterferon α-2b combination therapy. Hepatology40(Suppl. 1), 217A (2004) (Abstract 125).
   Google Scholar
• Howell CD, Jeffers LS, Cassidy W et al. Peginterferon α-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J. Viral Hepatol.13(6), 371–376 (2006).
   Google Scholar
• El-Kamary SS, Serwint JR, Joffe A, Santosham M, Duggan AK. Prevalence of hepatitis C virus infection in urban children. J. Pediatr.143, 54–59 (2003).
   Google Scholar
• Schwimmer JB, Balistreri WF. Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population. Semin. Liver Dis.20, 37–46 (2000).
   Web of Science ®Google Scholar
• Bortolotti F, Giacchino R, Varjo P et al. Recombinant interferon-α therapy in children with chronic hepatitis C. Hepatology22(6), 1623–1627 (1995).
   PubMedGoogle Scholar
• Wirth S, Lang T, Gehring S, Gerner P. Recombinant α-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology36(5), 1280–1284 (2002).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Peralta RP, Kelly DA, Haber B et al. Interferon α-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology42, 1010–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Schwarz, KB, Mohan P, Narkewicz MR et al. Safety, efficacy and pharmacokinetics of peginterferon α2a (40 kD) in children with chronic hepatitis C. J. Pediatr. Gastroenterol. Nutr.43(4), 499–505 (2006).
   PubMed Web of Science ®Google Scholar
• Kowala-Piaskowska A, Sluzewski W, Dworacki G et al. Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin. Infection35(3), 175–179 (2007).
   Google Scholar
• Bresci G, Del Corso L, Romanelli M et al. The use of recombinant interferon α-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J. Am. Geriatr. Soc.41(8), 857–862 (1993).
   PubMedGoogle Scholar
• Horiike N, Masumoto T, Nakanishi K et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J. Gastroenterol. Hepatol.10(3), 246–249 (1995).
   PubMedGoogle Scholar
• Honda T, Katano Y, Urano F et al. Efficacy of ribavirin plus interferon-a in patients aged >/=60 years with chronic hepatitis C. J. Gastroenterol. Hepatol.22(7), 989–995 (2007).
   PubMedGoogle Scholar
• Garcia-Retortillo M, Forns X, Llovet JM et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology40(3), 699–707 (2004).
   PubMed Web of Science ®Google Scholar
• Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl.9(11), S44–S47 (2003).
   Google Scholar
• Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut51(2), 248–252 (2002).
   PubMed Web of Science ®Google Scholar
• Kizilisik TA, Al-Sebayel M, Hammad A et al. Hepatitis C recurrence in liver transplant recipients. Transplant Proc.29, 2875–2877 (1997).
   Google Scholar
• Ghalib R, Pandula R, Kadhim T et al. Treatment of recurrent hepatitis C after liver transplantation with α-2a interferon plus ribavirin. Hepatology32(Suppl. 1), 291A (2000).
   Google Scholar
• Samuel D, Bizollon T, Feray C et al. Interferon α-ab plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology124, 642–650 (2003).
   PubMed Web of Science ®Google Scholar
• Wang, CS, Ko HH, Yoshida EM et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am. J. Transplant.6(7), 1586–1599 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandez I, Meneu JC, Colina F et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl.12(12), 1805–1812 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl.11(5), 479–489 (2005).
   Google Scholar
• Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy. Transplantation79(3), 261–268 (2005).
   PubMedGoogle Scholar
• Toniutto P, Fabris C, Fumo E et al. Pegylated versus standard interferon-α in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J. Gastroenterol. Hepatol.20(4), 577–582 (2005).
   PubMed Web of Science ®Google Scholar
• Cicinnati VR, Iacob S, Klein CG et al. Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation. Aliment Pharmacol. Ther.26(2), 291–303 (2007).
   Google Scholar
• Angelico M, Petrolati A, Lionetti R et al. A randomized study on Peg-interferon α-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J. Hepatol.46(6), 1009–1017 (2007).
   PubMed Web of Science ®Google Scholar
• Feray C, Samuel D, Gigou M et al. An open trial of interferon α recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology22(4 Pt 1), 1084–1089 (1995).
   PubMed Web of Science ®Google Scholar
• Feray C, Samuel D, Gigou M, Paradis V, Reynes M, Bismuth H. An open trial of interferon α-recombinant for hepatitis C after liver transplantation. Hepatology22, 1084–1089 (1995).
   PubMed Web of Science ®Google Scholar
• Yedibela S, Schuppan D, Muller V et al. Successful treatment of hepatitis C reinfection with interferon-α2b and ribavirin after liver transplantation. Liver Int.25(4), 717–722 (2005).
   Google Scholar
• Walter T, Dumortier J, Guillaud O et al. Rejection under alpha interferon therapy in liver transplant recipients. Am. J. Transplant.7(1), 177–184 (2007).
   PubMedGoogle Scholar
• Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients. N. Engl. J. Med.330, 1160–1161 (1994).
   Web of Science ®Google Scholar
• Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology38(3), 639–644 (2003).
   PubMed Web of Science ®Google Scholar
• Younossi ZM, McCullough AJ, Ong JP et al. Obesity and nonalcoholic fatty liver disease in chronic hepatitis C. J. Clin. Gastroenterol.38(8), 705–709 (2004).
   Google Scholar
• Hu KQ, Kyulo NL, Esrailian E et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J. Hepatol.40(1), 147–154 (2004).
   PubMed Web of Science ®Google Scholar
• Jian Wu Y, Shu Chen L, Gui Qiang W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int.26(2), 166–172 (2006).
   Google Scholar
• Chung RT, Andersen J, Volberding P et al. Peginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med.351(5), 451–459 (2004).
   PubMed Web of Science ®Google Scholar
• Cargnel A, Angeli E, Mainini A et al. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir. Ther.10(2), 309–317 (2005).
   PubMed Web of Science ®Google Scholar
• Perez-Olmeda M, Nunez M, Romero M et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS17(7), 1023–1028 (2003).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann. Intern. Med.140, 346–355 (2004).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon α-2a in patients with chronic hepatitis C. N. Engl. J. Med.343, 1666–1672 (2000).
   PubMed Web of Science ®Google Scholar
• Antonucci G, Longo MA, Angeletti C et al. The effect of age on response to therapy with peginterferon-α plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am. J. Gastroenterol.102(7), 1383–1391 (2007).
   PubMed Web of Science ®Google Scholar